Form 4: Versant Venture Capital Group Divests 200,000 Shares of LENZ Therapeutics

Versant Venture Capital VI, L.P., along with affiliated entities, reported the sale of 200,000 shares of LENZ Therapeutics, Inc. common stock for approximately $6.09 million.

Summary

• Versant Venture Capital VI, L.P., a 10% owner and director of LENZ Therapeutics, Inc., reported the sale of 200,000 shares of common stock.
• The transaction occurred on June 27, 2025, at a weighted average price of $30.465 per share, with prices ranging from $30.18 to $30.75.
• Following this transaction, Versant Venture Capital VI, L.P. directly holds 1,767,275 shares.
• Additionally, Versant Venture Capital VII, L.P. indirectly holds 1,047,912 shares, and Versant Vantage II, L.P. indirectly holds 842,162 shares.
• The total beneficial ownership by the Versant group after the sale is approximately 3,657,349 shares.

Sentiment

Score: 4

Explanation: The sale of a significant block of shares by a major institutional investor and director group could be perceived as a negative signal by the market, potentially indicating a reduction in their long-term commitment or a strategic exit. However, it is also a common and expected part of a venture capital firm's investment realization process.

Negatives

• A significant sale of 200,000 shares by a 10% owner and director group (Versant Venture Capital entities) could be perceived negatively by the market, potentially signaling a reduction in conviction or a move towards portfolio rebalancing.

Future Outlook

NA

Industry Context

This transaction represents a partial divestment by a venture capital firm, which is a common occurrence as VC funds mature and seek to realize returns on their investments. Such sales are part of the normal lifecycle for venture-backed companies that go public.

Related Party Transactions

• The reported sale of 200,000 shares of LENZ Therapeutics common stock by Versant Venture Capital VI, L.P. and its affiliated entities constitutes a related party transaction, as these entities are identified as a 10% owner and have director representation on the issuer's board.

Stakeholder Impact

• Shareholders may interpret the sale by a significant institutional investor and director group as a negative signal, potentially leading to increased selling pressure or a decline in investor confidence in LENZ Therapeutics' stock price.
• The transaction itself does not directly impact employees, customers, suppliers, or creditors, but any resulting stock price volatility could indirectly affect employee morale (if stock options are a significant part of compensation) or the company's ability to raise future capital.

Key Dates

Keywords

LENZ Therapeutics, Versant Venture Capital, SEC Form 4, Insider Sale, Stock Transaction, Beneficial Ownership, Venture Capital Divestment